Press release

Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis

Statistically significant (p=0.0177) reduction in knee pain at six monthsStatistically significant

Organogenesis Holdings Inc.May 2, 20245

Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis

About this update from Organogenesis Holdings Inc.

Statistically significant (p=0.0177) reduction in knee pain at six months Statistically significant (p

View stock analysis, news, and events for Organogenesis Holdings Inc.

More from Organogenesis Holdings Inc.

Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Chall...

July 27, 2026

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

July 9, 2026

All Organogenesis Holdings Inc. news →